BE571408A - - Google Patents
Info
- Publication number
- BE571408A BE571408A BE571408DA BE571408A BE 571408 A BE571408 A BE 571408A BE 571408D A BE571408D A BE 571408DA BE 571408 A BE571408 A BE 571408A
- Authority
- BE
- Belgium
- Prior art keywords
- vitamin
- emulsifier
- per
- water
- solution
- Prior art date
Links
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 51
- 229930003316 Vitamin D Natural products 0.000 claims description 38
- 229940046008 vitamin d Drugs 0.000 claims description 38
- 235000019166 vitamin D Nutrition 0.000 claims description 37
- 239000011710 vitamin D Substances 0.000 claims description 37
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 37
- 239000003995 emulsifying agent Substances 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 14
- 229930003231 vitamin Natural products 0.000 claims description 14
- 235000013343 vitamin Nutrition 0.000 claims description 14
- 239000011782 vitamin Substances 0.000 claims description 14
- 241000283690 Bos taurus Species 0.000 claims description 13
- 235000005282 vitamin D3 Nutrition 0.000 claims description 13
- 239000011647 vitamin D3 Substances 0.000 claims description 13
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 13
- 229940021056 vitamin d3 Drugs 0.000 claims description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000032696 parturition Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 125000006353 oxyethylene group Chemical group 0.000 claims description 9
- 208000007542 Paresis Diseases 0.000 claims description 8
- -1 polyoxyethylene Polymers 0.000 claims description 8
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- WBHHMMIMDMUBKC-QJWNTBNXSA-N ricinoleic acid Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O WBHHMMIMDMUBKC-QJWNTBNXSA-N 0.000 claims description 4
- 229960003656 ricinoleic acid Drugs 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 235000004443 Ricinus communis Nutrition 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 13
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 206010037660 Pyrexia Diseases 0.000 description 8
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 3
- 229960002061 ergocalciferol Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 239000011653 vitamin D2 Substances 0.000 description 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE571408A true BE571408A (OSRAM) |
Family
ID=189604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE571408D BE571408A (OSRAM) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE571408A (OSRAM) |
-
0
- BE BE571408D patent/BE571408A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0593601B1 (fr) | Nouvelles compositions a base de derives de la classe des taxanes | |
| CA2150576C (fr) | Compositions injectables a base de derives des taxanes | |
| FR2731617A1 (fr) | Compositions pharmaceutiques nouvelles contenant du propofol | |
| FR2914188A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| FR2474312A1 (fr) | Nouvelles compositions anti-microbiennes pour le traitement topique de l'acne vulgaire | |
| FR2458285A1 (fr) | Preparation pharmaceutique transdermique au dinitrate d'isosorbide | |
| Mineo et al. | Chemical specificity of short-chain fatty acids in stimulating insulin and glucagon secretion in sheep | |
| CN116270453A (zh) | 一种联苯苄唑溶液剂及其制备工艺 | |
| EP1458413B1 (fr) | Compositions pharmaceutiques a base de derives d azetidine | |
| OA12416A (fr) | Composition pharmaceutique de dronedarone pour administration parentérale. | |
| EP1377316B1 (fr) | Composition pharmaceutique a base de azalides pour application locale en ophtalmologie | |
| FR2692145A1 (fr) | Nouvelle composition à usage topique contenant de la diosmine. | |
| BE571408A (OSRAM) | ||
| WO1992010989A1 (fr) | Composition cosmetique ou pharmaceutique se presentant sous la forme d'un gel rigide, notamment en vue du maintien d'inclusions en son sein | |
| FI113745B (fi) | Menetelmä bioaktiivisia steroideja sisältävien farmaseuttisten emulsioiden valmistamiseksi | |
| BE1011216A3 (fr) | Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition. | |
| DE102007014947B4 (de) | Stabilisierte wässrige Lösungen von Ergolinverbindungen | |
| EP0271374B1 (fr) | Composition antibiotique aqueuse à usage vétérinaire | |
| BE536866A (OSRAM) | ||
| BE623396A (fr) | Procédé pour la préparation d'un diluant pharmaceutique | |
| BE529269A (OSRAM) | ||
| CH719763A2 (fr) | Composition pour application cutanée ou unguéale | |
| FR2820635A1 (fr) | Procede de preparation d'une creme a base d'acide hyaluronique | |
| BE897536A (fr) | Medicament a action analgestique | |
| DE1792448B2 (de) | Verfahren zur Herstellung von zur parenteralen Verabreichung geeigneten stabilen Lösungen von therapeutisch anwendbaren Benzodiazepinderivaten |